# Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors

> **NCT00389584** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of California, Davis** · enrollment: 30 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors
- Cognitive/Functional Effects
- Long-term Effects Secondary to Cancer Therapy in Adults
- Long-term Effects Secondary to Cancer Therapy in Children
- Poor Performance Status
- Unspecified Adult Solid Tumor, Protocol Specific
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** irinotecan hydrochloride
- **PROCEDURE:** cognitive assessment
- **PROCEDURE:** management of therapy complications
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00389584
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00389584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00389584, "Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00389584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*